Literature DB >> 12450787

ETV6-NTRK3--Trk-ing the primary event in human secretory breast cancer.

David M Euhus1, Charles F Timmons, Gail E Tomlinson.   

Abstract

In this issue of Cancer Cell, propose a single chromosomal translocation as the cause of a particularly troubling form of breast cancer, secretory carcinoma. They challenge widely held beliefs concerning breast carcinogenesis as well as beliefs concerning the absolute association of specific fusion genes with specific tumor types. Their data highlight the role of Trk signaling in breast cancer and also suggest a target for drug development.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12450787     DOI: 10.1016/s1535-6108(02)00184-8

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  17 in total

1.  TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts.

Authors:  Jamie L Croucher; Radhika Iyer; Nanxin Li; Valentina Molteni; Jon Loren; W Perry Gordon; Tove Tuntland; Bo Liu; Garrett M Brodeur
Journal:  Cancer Chemother Pharmacol       Date:  2014-11-14       Impact factor: 3.333

2.  AZ64 inhibits TrkB and enhances the efficacy of chemotherapy and local radiation in neuroblastoma xenografts.

Authors:  Radhika Iyer; Carly R Varela; Jane E Minturn; Ruth Ho; Anisha M Simpson; Jennifer E Light; Audrey E Evans; Huaqing Zhao; Kenneth Thress; Jeffrey L Brown; Garrett M Brodeur
Journal:  Cancer Chemother Pharmacol       Date:  2012-05-24       Impact factor: 3.333

3.  Mammary Analog Secretory Carcinoma (MASC) Involving the Thyroid Gland: A Report of the First 3 Cases.

Authors:  Jennifer Dettloff; Raja R Seethala; Todd M Stevens; Margaret Brandwein-Gensler; Barbara A Centeno; Kristen Otto; Julia A Bridge; Justin A Bishop; Marino E Leon
Journal:  Head Neck Pathol       Date:  2016-07-11

Review 4.  Modular nanotransporters for targeted intracellular delivery of drugs: folate receptors as potential targets.

Authors:  Tatiana A Slastnikova; Andrey A Rosenkranz; Michael R Zalutsky; Alexander S Sobolev
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

5.  Cardiac metastasis and hypertrophic osteoarthropathy in recurrent infantile fibrosarcoma.

Authors:  Nirali N Shah; Mitchell R Price; David M Loeb
Journal:  Pediatr Blood Cancer       Date:  2011-08-18       Impact factor: 3.167

6.  ETV6-NTRK3 fusion oncogene initiates breast cancer from committed mammary progenitors via activation of AP1 complex.

Authors:  Zhe Li; Cristina E Tognon; Frank J Godinho; Laura Yasaitis; Hanno Hock; Jason I Herschkowitz; Chris L Lannon; Eunah Cho; Seong-Jin Kim; Roderick T Bronson; Charles M Perou; Poul H Sorensen; Stuart H Orkin
Journal:  Cancer Cell       Date:  2007-12       Impact factor: 31.743

Review 7.  ETS gene fusions in prostate cancer.

Authors:  Jeremy P Clark; Colin S Cooper
Journal:  Nat Rev Urol       Date:  2009-08       Impact factor: 14.432

8.  Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model.

Authors:  Radhika Iyer; Lea Wehrmann; Rebecca L Golden; Koumudi Naraparaju; Jamie L Croucher; Suzanne P MacFarland; Peng Guan; Venkatadri Kolla; Ge Wei; Nicholas Cam; Gang Li; Zachary Hornby; Garrett M Brodeur
Journal:  Cancer Lett       Date:  2016-01-18       Impact factor: 8.679

9.  Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity.

Authors:  Alexandra Van Keymeulen; May Yin Lee; Marielle Ousset; Sylvain Brohée; Sandrine Rorive; Rajshekhar R Giraddi; Aline Wuidart; Gaëlle Bouvencourt; Christine Dubois; Isabelle Salmon; Christos Sotiriou; Wayne A Phillips; Cédric Blanpain
Journal:  Nature       Date:  2015-08-12       Impact factor: 49.962

10.  Clinicopathologic and Molecular Characterization of Four Cases of Pediatric Salivary Secretory Carcinoma (SSC), One with ETV6-RET Fusion.

Authors:  Cláudia M Salgado; Rita Alaggio; Miguel Reyes-Múgica; Angelica Zin; Rita de Vito
Journal:  Head Neck Pathol       Date:  2021-01-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.